Multicenter, USA - 04 Apr `17Incyte: A Study of Ruxolitinib 1,5% cream

Official Title: A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

In Brief: The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

Description: Ruxolitinib cream 1.5% twice-daily for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension

Details: Check Incyte announcement or download pdf with a scientific presentation from UMass.

Ages Eligible: 18 Years to 75 Years

Start Date: April 19, 2017

Completion Date (estimated): September 2021

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03099304
Other Study ID Numbers: INCB 18424-211 

Location: 26 locations across the United States

Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

FAQOther Questions

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...

  • Isn't it just a cosmetic disorder?

    Contrary to popular belief, vitiligo is not a cosmetic disorder but a systemic disease affecting the largest body organ and other vital systems, with multiple comorbidities. Fo...

  • I have vitiligo: will my children have vitiligo, too?

    Children born to parents who both have the disorder are more likely to develop vitiligo. However, most children will not get vitiligo even if one parent has it. In children wit...